BLFS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

24.05M

+5.9%

-0.008

-103.08%

25.62M

+7%

0.015

-250%

27.23M

+7.12%

0.025

-107.58%

Estimates Revision

The market is revising Downward the revenue expectations for BioLife Solutions, Inc. (BLFS) for FY2025, with the revenue forecasts being adjusted by -3.67% over the past three months. During the same period, the stock price has changed by -9.44%.

Revenue Estimates for FY2025

Revise Downward

-3.67%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-9.44%

In Past 3 Month

Stock Price

Go Down

-9.44%

In Past 3 Month

8 Analyst Rating

Wall Street analysts forecast BLFS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLFS is 32.29 USD with a low forecast of 30.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

30.00

Averages

32.29

High

34.00

Current: 0.000

Low

30.00

Averages

32.29

High

34.00

Northland

Outperform

maintain

$31 -> $34

2026-01-05

New

Reason

Northland

Price Target

$31 -> $34

2026-01-05

New

maintain

Outperform

Reason

Northland raised the firm's price target on BioLife Solutions to $34 from $31 and keeps an Outperform rating on the shares, which were also named a 2026 Top Pick. Following its re-establishment as a pure play and its control of the biopreservation layer in cell and gene therapy development, BioLife is "structurally locked into large pharma and biotech programs from initiation through commercialization," the analyst tells investors.

H.C. Wainwright

Buy

maintain

$30 -> $32

2025-08-08

Reason

H.C. Wainwright

Price Target

$30 -> $32

2025-08-08

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on BioLife Solutions to $32 from $30 and keeps a Buy rating on the shares following the Q2 beat.

Stephens

Overweight

initiated

$30

2025-07-21

Reason

Stephens

Price Target

$30

2025-07-21

initiated

Overweight

Reason

Stephens resumed coverage of BioLife Solutions with an Overweight rating and $30 price target and named the stock as the analyst's "Best Idea." BioLife is now positioned as more consumable-focused and closely aligned with the cell and gene therapy industry following the sale of SciSafe, CBS, and Stirling, the analyst tells investors. The Media segment "represents a crown jewel asset" as it has about 70% market share and high-60%-plus gross margins, serving as the key growth driver in the near-term, the analyst added.

HC Wainwright & Co.

Yi Chen

Strong Buy

Maintains

$27 → $30

2025-03-06

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$27 → $30

2025-03-06

Maintains

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for BioLife Solutions Inc (BLFS.O) is 411.90, compared to its 5-year average forward P/E of -292.15. For a more detailed relative valuation and DCF analysis to assess BioLife Solutions Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-292.15

Current PE

411.90

Overvalued PE

630.10

Undervalued PE

-1214.41

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

86.60

Current EV/EBITDA

39.30

Overvalued EV/EBITDA

197.71

Undervalued EV/EBITDA

-24.50

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

8.54

Current PS

10.86

Overvalued PS

11.81

Undervalued PS

5.28

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

BLFS News & Events

Events Timeline

No data

News

6.5

2025-12-26Yahoo Finance

Pinnacle Financial Partners Trading 32.3% Below Fair Value Amid Growth Prospects

6.5

2025-12-25Yahoo Finance

Workday and Dycom Industries Highlighted as Undervalued with Significant Growth Potential

5.0

2025-12-11NASDAQ.COM

BioLife Solutions' CFO Offloads 30,000 Shares

People Also Watch

Frequently Asked Questions

What is BioLife Solutions Inc (BLFS) stock price today?

The current price of BLFS is 24.86 USD — it has decreased -0.36 % in the last trading day.

What is BioLife Solutions Inc (BLFS)'s business?

BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal cryogenic vials, which are rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company’s ThawSTAR product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.

What is the price predicton of BLFS Stock?

What is BioLife Solutions Inc (BLFS)'s revenue for the last quarter?

BioLife Solutions Inc revenue for the last quarter amounts to 28.07M USD, increased 31.21 % YoY.

What is BioLife Solutions Inc (BLFS)'s earnings per share (EPS) for the last quarter?

BioLife Solutions Inc. EPS for the last quarter amounts to 0.01 USD, decreased -125.00 % YoY.

What changes have occurred in the market's expectations for BioLife Solutions Inc (BLFS)'s fundamentals?

How many employees does BioLife Solutions Inc (BLFS). have?

BioLife Solutions Inc (BLFS) has 159 emplpoyees as of January 10 2026.

What is BioLife Solutions Inc (BLFS) market cap?

Today BLFS has the market capitalization of 1.20B USD.